OBJECTIVES: To describe independent predictors for the development of microalbuminuria and progression to macroalbuminuria in those with childhood onset type 1 diabetes. DESIGN: Prospective observational study with follow-up for 9.8 (SD 3.8) years. SETTING: Oxford regional prospective study. PARTICIPANTS: 527 participants with a diagnosis of type 1 diabetes at mean age 8.8 (SD 4.0) years. MAIN OUTCOME MEASURES: Annual measurement of glycated haemoglobin (HbA1c) and assessment of urinary albumin:creatinine ratio. RESULTS: Cumulative prevalence of microalbuminuria was 25.7% (95% confidence interval 21.3% to 30.1%) after 10 years of diabetes and 50.7% (40.5% to 60.9%) after 19 years of diabetes and 5182 patient years of follow-up. The only modifiable adjusted predictor for microalbuminuria was high HbA1c concentrations (hazard ratio per 1% rise in HbA1c 1.39, 1.27 to 1.52). Blood pressure and history of smoking were not predictors. Microalbuminuria was persistent in 48% of patients. Cumulative prevalence of progression from microalbuminuria to macroalbuminuria was 13.9% (12.9% to 14.9%); progression occurred at a mean age of 18.5 (5.8) years. Although the sample size was small, modifiable predictors of macroalbuminuria were higher HbA(1c) levels and both persistent and intermittent microalbuminuria (hazard ratios 1.42 (1.22 to 1.78), 27.72 (7.99 to 96.12), and 8.76 (2.44 to 31.44), respectively). CONCLUSION: In childhood onset type 1 diabetes, the only modifiable predictors were poor glycaemic control for the development of microalbuminuria and poor control and microalbuminuria (both persistent and intermittent) for progression to macroalbuminuria. Risk for macroalbuminuria is similar to that observed in cohorts with adult onset disease but as it occurs in young adult life early intervention in normotensive adolescents might be needed to improve prognosis.
OBJECTIVES: To describe independent predictors for the development of microalbuminuria and progression to macroalbuminuria in those with childhood onset type 1 diabetes. DESIGN: Prospective observational study with follow-up for 9.8 (SD 3.8) years. SETTING: Oxford regional prospective study. PARTICIPANTS: 527 participants with a diagnosis of type 1 diabetes at mean age 8.8 (SD 4.0) years. MAIN OUTCOME MEASURES: Annual measurement of glycated haemoglobin (HbA1c) and assessment of urinary albumin:creatinine ratio. RESULTS: Cumulative prevalence of microalbuminuria was 25.7% (95% confidence interval 21.3% to 30.1%) after 10 years of diabetes and 50.7% (40.5% to 60.9%) after 19 years of diabetes and 5182 patient years of follow-up. The only modifiable adjusted predictor for microalbuminuria was high HbA1c concentrations (hazard ratio per 1% rise in HbA1c 1.39, 1.27 to 1.52). Blood pressure and history of smoking were not predictors. Microalbuminuria was persistent in 48% of patients. Cumulative prevalence of progression from microalbuminuria to macroalbuminuria was 13.9% (12.9% to 14.9%); progression occurred at a mean age of 18.5 (5.8) years. Although the sample size was small, modifiable predictors of macroalbuminuria were higher HbA(1c) levels and both persistent and intermittent microalbuminuria (hazard ratios 1.42 (1.22 to 1.78), 27.72 (7.99 to 96.12), and 8.76 (2.44 to 31.44), respectively). CONCLUSION: In childhood onset type 1 diabetes, the only modifiable predictors were poor glycaemic control for the development of microalbuminuria and poor control and microalbuminuria (both persistent and intermittent) for progression to macroalbuminuria. Risk for macroalbuminuria is similar to that observed in cohorts with adult onset disease but as it occurs in young adult life early intervention in normotensive adolescents might be needed to improve prognosis.
Authors: Rakesh Amin; Carl Schultz; Ken Ong; Jan Frystyk; R Neil Dalton; Les Perry; Hans Ørskov; David B Dunger Journal: Diabetes Care Date: 2003-05 Impact factor: 19.112
Authors: Reinhard W Holl; Peter G F Swift; Henrik B Mortensen; Helle Lynggaard; Phillip Hougaard; Henk-Jan Aanstoot; Francesco Chiarelli; Denis Daneman; Thomas Danne; Harry Dorchy; Patrick Garandeau; Steven Greene; Hilary M C V Hoey; Eero A Kaprio; Mirjana Kocova; Pedro Martul; Nobuo Matsuura; Kenneth J Robertson; Eugen J Schoenle; Oddmund Sovik; Rosa-Maria Tsou; Maurizio Vanelli; Jan Aman Journal: Eur J Pediatr Date: 2002-11-26 Impact factor: 3.183
Authors: J H Warram; L J Scott; L S Hanna; M Wantman; S E Cohen; L M Laffel; L Ryan; A S Krolewski Journal: Diabetes Date: 2000-01 Impact factor: 9.461
Authors: C J Schultz; T Konopelska-Bahu; R N Dalton; T A Carroll; I Stratton; E A Gale; A Neil; D B Dunger Journal: Diabetes Care Date: 1999-03 Impact factor: 19.112
Authors: Rakesh Amin; Charles Turner; Sara van Aken; Teresa Konopelska Bahu; Angela Watts; David R M Lindsell; R Neil Dalton; David B Dunger Journal: Kidney Int Date: 2005-10 Impact factor: 10.612
Authors: B S Olsen; A Sjølie; P Hougaard; J Johannesen; K Borch-Johnsen; K Marinelli; B Thorsteinsson; S Pramming; H B Mortensen Journal: J Diabetes Complications Date: 2000 Nov-Dec Impact factor: 2.852
Authors: Bruce A Perkins; Linda H Ficociello; Kristen H Silva; Dianne M Finkelstein; James H Warram; Andrzej S Krolewski Journal: N Engl J Med Date: 2003-06-05 Impact factor: 91.245
Authors: Paul Z Benitez-Aguirre; Maria E Craig; Alicia J Jenkins; Patricia H Gallego; Janine Cusumano; Anthony C Duffin; Stephen Hing; Kim C Donaghue Journal: J Diabetes Sci Technol Date: 2012-03-01
Authors: N Minuto; V Emmanuele; M Vannati; C Russo; C Rebora; S Panarello; A Pistorio; R Lorini; G d'Annunzio Journal: J Endocrinol Invest Date: 2011-10-06 Impact factor: 4.256
Authors: M Loredana Marcovecchio; Paivi H Tossavainen; Carlo L Acerini; Timothy G Barrett; Julie Edge; Andrew Neil; Julian Shield; Barry Widmer; R Neil Dalton; David B Dunger Journal: Diabetes Care Date: 2009-11-16 Impact factor: 19.112